Centre for Human Drug Research

Leiden 75 trials 25 recruiting

75 Registered trials

25 Currently recruiting

Organisation

Centre for Human Drug Research

Location

Leiden, Netherlands

Identifier

ORG-100008266

Address

Zernikedreef 8, 2333 CL, Netherlands

Departments

-
#1003: Internal Medicine
9001: Internal Medicine
Center for Human Drug Research
CHDR
Department of Neurology
Dermatology
Experimental Medicine
Immunology
Infectious Diseases
Internal Medicine
n.a.
NA
Neurology
Neurology dep.
Pain
Psychiatry
Psychology
Translational Dermatology

Clinical trials at this site (75)

Search interface

Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic… Ended

2022-503009-39-00 Subacute Cutaneous Lupus Erythematosus 3 2024-06-04
Intradermal LPS to study vascular responses Ended

2024-512377-27-00 Immunological/cardiovascular conditions 3 2024-05-28
A Randomized, double-blind, placebo-controlled, three-way cross-over study to assess the pharmacodynamic effects of an authorised and a new … Ended

2024-510721-26-00 neuropathic pain 3 2024-05-17
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1117570 in Healthy Adults Ended

2023-508814-40-00 Neurological and neuropsychiatric conditions 3 2024-03-11
This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adu… Ended

2023-504800-28-00 Chronic Inducible Urticaria 3 2024-02-23
This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adu… Ended

2023-504799-94-00 Chronic Spontaneous Urticaria 4 2024-02-20
A controlled human rhinovirus infection study of 2-Deoxy-D-Glucose in healthy adults. Ended

2023-509311-91-01 Rhinovirus-associated illness 4 2024-02-15
Feasibility and tolerability of 28 days intravaginal oxybutynin via the MedRing OAB system Ended

2023-508692-36-00 Overactive bladder 3 2024-02-06
Safety, tolerability, pharmacokinetics and pharmacodynamics of ARV-102 in healthy participants Ended

2023-507910-28-00 Parkinson's Disease 1 2024-01-04
CBD, amitriptyline and tramadol drug-drug interaction study Ended

2023-508428-36-00 Neurological assessments 4 2023-12-19
Imatinib PD in healthy subjects Ended

2023-504958-35-00 Immuno-oncology assessments 3 2023-12-13
Study to assess the effects of oral cannabidiol in healthy male subjects on CNS using the NeuroCart test battery and TMS. Ended

2023-508311-23-00 Neurological assessments 4 2023-11-20
A randomized, double-blind, double dummy, placebo-controlled, four-way cross-over study to investigate the analgesic effects and CNS effects… Ended

2023-505793-15-00 Chronic pain 3 2023-10-30
SAD and MAD study of VES001 Ended

2023-505847-38-00 Frontotemporal dementia (FTD) 1 2023-10-11
A Trial Investigating the pain-relieving properties of Lu AG06474 in Healthy Adult Participants Ended

2023-503987-18-00 Pain 3 2023-10-03
A study of the safety of the new investigational drug CVN293 in healthy volunteers, and how CVN293 is taken up and processed by the human bo… Ended

2023-506114-49-00 Neurodegenerative disorders 1 2023-08-15
SAD and MAD of VENT-02 in healthy volunteers Ended

2023-505546-26-00 Neuroinflammatory and neurodegenerative diseases 1 2023-07-21
A Phase 2, Single-Blind, Placebo-Controlled Trial to Evaluate the Photoparoxysmal Electroencephalogram Response, Safety, Tolerability, and P… Ended

2023-504803-10-00 IPS induced photoparoxysmal electroencephalogram respon 4 2023-06-15
Transcranial Magnetic Stimulation (TMS) Evaluation of Central Nervous System (CNS) Pharmacodynamic (PD) Activity of Brexanolone in Healthy M… Ended

2022-503019-40-00 NA, PD study in Healthy Volunteers 3 2023-05-11
Safety, tolerability and effect of DLX-001 in healthy volunteers Ended

2023-503390-38-00 Unipolar depression (UD) 1 2023-04-14
A Randomized, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Single And Multiple Ascending Dose Study To Evaluate Safety, Tolerabilit… Ended

2024-512987-74-00 Disorders characterized by a deficit in GABAergic signa 3 2023-02-27
A study investigating the safety, tolerability, absorption, excretion and effects of a new drug for the treatment of epilepsy. Ended

2022-502638-17-00 Epilepsy 3 2023-02-03
A study investigating the pain-relieving effects of a new drug in healthy adults Ended

2022-501804-80-00 Acute and chronic neuropathic pain secondary to diabeti 3 2022-11-17
Study investigating the safety and efficacy of a new iodine formulation called DLQ03 in a wound-healing model in patients with atopic eczema Ended

2022-500647-21-00 Atopic dermatitis (Eczema) 7 2022-08-04